Redwire (RDW) announced that NASA has awarded the company an additional $4M to support new drug development investigations on the International Space Station using Redwire’s Pharmaceutical In-space Laboratory technology. This additional funding expands an existing task order under a $25M, five-year indefinite-delivery/indefinite-quantity contract through NASA’s In Space Production Applications program.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDW:
- Redwire Corporation Signals Growth Amid Profit Pressures
- Redwire upgraded to Buy from Hold at Truist
- Redwire price target lowered to $12 from $13 at Jefferies
- Redwire price target raised to $12 from $11 at Canaccord
- Tariffs and Trade Tensions Threaten Redwire Corporation’s Costs, Competitiveness and Global Demand